Skip to main content
Premium Trial:

Request an Annual Quote

Spotfire Expands Line of DecisionSite Apps With Pre-Configured Functional Genomics Tool

Premium

With the concurrent launch this week of the new version of its horizontal DecisionSite platform as well as a pre-configured DecisionSite for Functional Genomics, Spotfire is pushing ahead with its goal of meeting the broad range of analytical needs along the discovery pipeline. David Butler, vice president of product strategy and marketing at Spotfire, said the company hopes to see DecisionSite used along the key processes of the entire enterprise — from product development to supply chain management, manufacturing, finance, and performance management.

Butler said the DecisionSite family meets the integration needs of many pharmaceutical companies that are not only seeking to integrate research data, but “all of the activities of the pharmaceutical company.”

Among other new features, DecisionSite 6.2 offers an XML-based application manager and a new dynamic display. DecisionSite 6.2 also provides the platform for the pre-configured DecisionSite applications. In addition to DecisionSite for Functional Genomics, the company released its pre-configured Decision- Site for Lead Discovery in April. Spotfire is also launching pre-configured applications for process analysis and map interaction services.

DecisionSite for Functional Genomics can access and merge information from any combination of relational database systems, according to Spotfire, although the company partnered with Affymetrix and Incyte Genomics to ensure access to their databases. The package also offers Spotfire’s analytical components and visualization tools to help users analyze gene expression data.

Bill Ladd, director of bioinformatics at Spotfire, said customers appreciate the flexibility of purchasing only the underlying DecisionSite architecture or a pre-configured package for a particular application. Users have a choice of configuring DecisionSite themselves for different data sources and then adding on the pre-configured packages, or buying the entire solution at once.

Butler said that an out-of-the box bio- and chem-informatics solution could be built using DecisionSite for Functional Genomics along with DecisionSite for Lead Discovery, but the underlying DecisionSite architecture would allow users to configure it for other environments as well. Pricing for a system usually begins at $50,000 for a company trying out the system. Deployment in a single department could run in the $200,000-$400,000 range. Research-wide deals are generally in the seven figures, Butler said.

GlaxoSmithKline, BioGen, and Cold Spring Harbor Laboratory are among Spotfire’s DecisionSite customers. GlaxoSmithKline also opted for the pre-configured Lead Discovery component. Butler said several customers are beta testing the Functional Genomics pre-configured component.

— BT

Filed under

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.